Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
AS ONE Corporation (7476.T)
Osaka, JP
AS ONE Corporation, a Japanese company with a global presence, specializes in the distribution of a wide array of scientific instruments, research equipment, and essential products for nursing and healthcare. Its diverse catalog of scientific instruments includes devices for temperature and humidity control, alongside measuring and surveying tools. It also supplies versatile equipment for laboratory processes such as cooling, heating, mixing, absorption, pressurization, and material conveyance. For biotechnology, AS ONE provides microscopes, glass slides, and tissue culture products. Precision work and analytical technology are supported by magnifying glasses, filters, and dispensing apparatus. Essential research facility equipment encompasses experimental platforms, fume hoods, pharmaceutical storage units, general storage solutions, wagons, laboratory seating, and material handling gear. Additionally, the company offers fundamental lab consumables like various containers for samples, reagents, and materials; indispensable glassware and plasticware such as beakers and flasks; hoses, tubes, and connectors; along with practical items like tapes, labels, timers, packaging machinery, tools, and office supplies tailored for laboratory environments. The company also supplies industrial-grade equipment, including dehumidifying storage solutions, organizational and conveyance systems, and various sterilization, disinfecting, and cleaning products such as ultrasonic cleaners, detergents, and drying tools. Its offerings extend to personal protective equipment like safety glasses, masks, and gloves. Furthermore, AS ONE provides specialized items for clean rooms, including specific tools, containers, dust-proof apparel, anti-static products, and essential clean room mats. For the medical and nursing sectors, AS ONE provides hospital and nursing instruments, encompassing PPE like white gowns, masks, and gloves. It supplies rack systems designed for nursing stations, a diverse range of products, supplies, and equipment crucial for hospital nursing or general care, along with sterilizers and sterilization lockers. The company further offers mobility and patient comfort items such as care cars, beds, and a selection of bathing and sanitary products. Established in Osaka, Japan, in 1933, the company continues to maintain its headquarters there.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.16% | -3.88% | -5.65% | -7.13% | -16.45% | -14.79% | -11.34% | -26.31% | -34.51% | +97.35% | +574.85% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Distribution: +5.6%+6.7% ★ Q1'26: +11.0% (vs Q1'25)
-
EPS growth Medical - Distribution: +4.9%+11.7% ★ Q1'26: +9.7% (vs Q1'25)
-
FCF margin FCF growth · Medical - Distribution: +37.6%+3.7% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Distribution: +3.0%+11.6% ★ Q1'26: +10.8% (vs Q1'25)
-
ROIC Medical - Distribution: +5.7%+16.6% ★ Q1'26: +18.0% (vs Q1'25)
-
Share dilution Medical - Distribution: +0.0%-0.2% ★ Q1'26: -0.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×0.32× ★ Q1'26: 0.30× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 4 Rev. Ana. 4 EPS Ana. |
Mar 2027 4 Rev. Ana. 4 EPS Ana. |
Mar 2028 4 Rev. Ana. 4 EPS Ana. |
Mar 2029 1 Rev. Ana. 2 EPS Ana. |
Mar 2030 1 Rev. Ana. 2 EPS Ana. |
Mar 2031 1 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
52.04B
est: 53.00B (-1.8%)
|
53.58B
est: 54.65B (-2.0%)
|
55.95B
est: 56.40B (-0.8%)
|
60.96B
est: 61.30B (-0.6%)
|
66.73B
est: 67.24B (-0.8%)
|
70.39B
est: 69.85B (+0.8%)
|
81.61B
est: 79.11B (+3.2%)
|
86.95B
est: 86.00B (+1.1%)
|
91.42B
est: 93.77B (-2.5%)
|
95.54B
est: 97.97B (-2.5%)
|
103.75B
est: 103.75B (+0.0%)
|
109.26B
108.16B – 111.52B
+5.3% YoY
|
116.65B
114.84B – 120.08B
+6.8% YoY
|
124.28B
119.93B – 129.23B
+6.5% YoY
|
127.36B
124.10B – 131.79B
+2.5% YoY
|
133.49B
130.08B – 138.14B
+4.8% YoY
|
139.24B
135.68B – 144.09B
+4.3% YoY
|
| EBITDA |
7.04B
est: 7.21B (-2.3%)
|
6.80B
est: 7.43B (-8.5%)
|
7.11B
est: 7.67B (-7.4%)
|
7.47B
est: 8.34B (-10.5%)
|
8.52B
est: 9.15B (-6.9%)
|
9.54B
est: 9.50B (+0.4%)
|
11.59B
est: 10.76B (+7.7%)
|
11.07B
est: 11.70B (-5.4%)
|
13.04B
est: 12.76B (+2.2%)
|
12.26B
est: 12.93B (-5.2%)
|
13.40B
est: 13.69B (-2.2%)
|
14.42B
14.27B – 14.72B
+5.3% YoY
|
15.39B
15.16B – 15.85B
+6.8% YoY
|
16.40B
15.83B – 17.05B
+6.5% YoY
|
16.81B
16.38B – 17.39B
+2.5% YoY
|
17.62B
17.17B – 18.23B
+4.8% YoY
|
18.38B
17.91B – 19.01B
+4.3% YoY
|
| EBIT |
5.98B
est: 6.20B (-3.5%)
|
5.84B
est: 6.39B (-8.6%)
|
6.09B
est: 6.60B (-7.7%)
|
6.60B
est: 7.17B (-8.0%)
|
7.56B
est: 7.87B (-3.9%)
|
8.55B
est: 8.17B (+4.6%)
|
9.89B
est: 9.26B (+6.9%)
|
9.34B
est: 10.06B (-7.2%)
|
11.40B
est: 10.97B (+3.9%)
|
10.44B
est: 11.15B (-6.4%)
|
11.59B
est: 11.81B (-1.8%)
|
12.44B
12.31B – 12.69B
+5.3% YoY
|
13.28B
13.07B – 13.67B
+6.8% YoY
|
14.14B
13.65B – 14.71B
+6.5% YoY
|
14.49B
14.12B – 15.00B
+2.5% YoY
|
15.19B
14.80B – 15.72B
+4.8% YoY
|
15.85B
15.44B – 16.40B
+4.3% YoY
|
| Net Income |
3.87B
est: 3.59B (+7.9%)
|
3.88B
est: 3.71B (+4.5%)
|
4.21B
est: 3.91B (+7.8%)
|
4.68B
est: 4.32B (+8.3%)
|
5.26B
est: 5.19B (+1.5%)
|
5.97B
est: 5.65B (+5.5%)
|
5.99B
est: 5.56B (+7.8%)
|
7.20B
est: 6.51B (+10.6%)
|
8.11B
est: 7.84B (+3.5%)
|
7.50B
est: 7.69B (-2.5%)
|
8.23B
est: 8.55B (-3.7%)
|
9.18B
8.93B – 9.19B
+7.4% YoY
|
9.74B
9.37B – 9.96B
+6.1% YoY
|
10.47B
10.05B – 10.72B
+7.6% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
—
— – —
|
| SGA |
9.48B
est: 10.14B (-6.4%)
|
10.29B
est: 10.45B (-1.5%)
|
10.75B
est: 10.79B (-0.3%)
|
11.81B
est: 11.72B (+0.7%)
|
13.01B
est: 12.86B (+1.2%)
|
13.37B
est: 13.36B (+0.1%)
|
16.01B
est: 15.13B (+5.8%)
|
16.19B
est: 16.45B (-1.6%)
|
17.03B
est: 17.93B (-5.0%)
|
18.80B
est: 18.52B (+1.5%)
|
19.71B
est: 19.62B (+0.5%)
|
20.66B
20.45B – 21.09B
+5.3% YoY
|
22.06B
21.72B – 22.71B
+6.8% YoY
|
23.50B
22.68B – 24.44B
+6.5% YoY
|
24.08B
23.47B – 24.92B
+2.5% YoY
|
25.24B
24.60B – 26.12B
+4.8% YoY
|
26.33B
25.66B – 27.25B
+4.3% YoY
|
| EPS |
50.48
est: 49.98 (+1.0%)
|
50.60
est: 51.76 (-2.2%)
|
55.22
est: 54.48 (+1.4%)
|
62.27
est: 60.28 (+3.3%)
|
70.50
est: 72.33 (-2.5%)
|
79.90
est: 78.83 (+1.4%)
|
80.14
est: 77.45 (+3.5%)
|
96.34
est: 90.75 (+6.2%)
|
109.45
est: 109.28 (+0.2%)
|
103.65
est: 106.60 (-2.8%)
|
114.88
est: 115.00 (-0.1%)
|
126.90
124.76 – 128.33
+10.3% YoY
|
135.47
130.84 – 139.09
+6.8% YoY
|
145.33
140.31 – 149.63
+7.3% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
—
— – —
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-11 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-08 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-01 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-15 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Takuji Iuchi | Chairman, President & Chief Executive Officer | 123M | male |
| Jun Machida | Head of Supply Chain Management Division | — | — |
| Kazuhito Yamada | MD, Chief Operating Officer & Director | — | male |
| Keisuke Nishikawa | Chief Financial Officer & Director | — | male |
| Masataka Maruhashi | Head of DX Development Division | — | — |
| Mitsushige Kimura | GM of Sales Division, Officer in charge of Professional Business, GM of Tokyo Office | — | male |
| Toru Kaneno | Head of Specialized Business Division | — | — |
| Isamu Hayashi | Corporation Managing Director | — | — |
| Toshiki Hara | Senior MD, CIO & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 7476.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
